Trial Profile
Observational Study on the Use of Xydalba: A Multicenter, Prospective Study to Characterize the Use of Xydalba in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2021
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections; Bacterial skin diseases
- Focus Therapeutic Use
- Sponsors Correvio
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 13 Jul 2020 Planned End Date changed from 1 Aug 2020 to 30 Sep 2020.
- 13 Jul 2020 Status changed from recruiting to active, no longer recruiting.